SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001725160-24-000111
Filing Date
2024-05-09
Accepted
2024-05-09 19:46:59
Documents
3
Period of Report
2024-05-09

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1715298409.html 4  
1 FORM 4 wk-form4_1715298409.xml 4 3410
2 EX-24 dhausmanpoaforworkiva.htm EX-24 4073
3 GRAPHIC dhausmanpoaforworkiva001.jpg GRAPHIC 251157
  Complete submission text file 0001725160-24-000111.txt   355217
Mailing Address C/O ONCOTHYREON INC. 2601 FOURTH AVE, SUITE 500 SEATTLE WA 98121
Business Address
HAUSMAN DIANA (Reporting) CIK: 0001563992 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39263 | Film No.: 24932514

Mailing Address 1359 BROADWAY, SUITE 801 NEW YORK NY 10018
Business Address 1359 BROADWAY, SUITE 801 NEW YORK NY 10018 (212) 433-3791
Zentalis Pharmaceuticals, Inc. (Issuer) CIK: 0001725160 (see all company filings)

IRS No.: 823607803 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)